PL398077A1 - Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego - Google Patents

Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego

Info

Publication number: PL398077A1
Authority: PL; Poland
Prior art keywords: composition; drug; manufacturing; treatment; multiple sclerosis
Prior art date: 2012-02-10

Application number

PL398077A

Other languages

English (en)

Inventor

Krzysztof Selmaj

Marian Szczepanik

Original Assignee

Krzysztof Selmaj

Marian Szczepanik

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-10

Filing date

2012-02-10

Publication date

2012-08-27

2012-02-10 Application filed by Krzysztof Selmaj, Marian Szczepanik filed Critical Krzysztof Selmaj

2012-02-10 Priority to PL398077A priority Critical patent/PL398077A1/pl

2012-08-27 Publication of PL398077A1 publication Critical patent/PL398077A1/pl

2013-02-08 Priority to SI201331085T priority patent/SI2812351T1/sl

2013-02-08 Priority to PL13710308T priority patent/PL2812351T3/pl

2013-02-08 Priority to US14/377,903 priority patent/US20150080313A1/en

2013-02-08 Priority to DK13710308.1T priority patent/DK2812351T3/en

2013-02-08 Priority to EP13710308.1A priority patent/EP2812351B1/en

2013-02-08 Priority to ES13710308.1T priority patent/ES2684725T3/es

2013-02-08 Priority to HUE13710308A priority patent/HUE039044T2/hu

2013-02-08 Priority to PT137103081T priority patent/PT2812351T/pt

2013-02-08 Priority to PCT/EP2013/052615 priority patent/WO2013117742A2/en

2018-08-02 Priority to US16/053,217 priority patent/US20190201484A1/en

Links

239000000203 mixture Substances 0.000 title abstract 3
239000003814 drug Substances 0.000 title abstract 2
229940079593 drug Drugs 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title abstract 2
201000006417 multiple sclerosis Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
230000002500 effect on skin Effects 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
102000047918 Myelin Basic Human genes 0.000 abstract 1
102000006386 Myelin Proteins Human genes 0.000 abstract 1
108010083674 Myelin Proteins Proteins 0.000 abstract 1
101710107068 Myelin basic protein Proteins 0.000 abstract 1
102000016202 Proteolipids Human genes 0.000 abstract 1
108010010974 Proteolipids Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000004248 oligodendroglia Anatomy 0.000 abstract 1
238000011200 topical administration Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Marine Sciences & Fisheries (AREA)
Cell Biology (AREA)
Hematology (AREA)
Rehabilitation Therapy (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL398077A 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego PL398077A1 (pl)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
PL398077A PL398077A1 (pl)	2012-02-10	2012-02-10	Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
PCT/EP2013/052615 WO2013117742A2 (en)	2012-02-10	2013-02-08	Pharmaceutical composition for the treatment of multiple sclerosis
DK13710308.1T DK2812351T3 (en)	2012-02-10	2013-02-08	Pharmaceutical composition for the treatment of multiple sclerosis
PL13710308T PL2812351T3 (pl)	2012-02-10	2013-02-08	Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego
US14/377,903 US20150080313A1 (en)	2012-02-10	2013-02-08	Pharmaceutical composition for the treatment of multiple sclerosis
SI201331085T SI2812351T1 (sl)	2012-02-10	2013-02-08	Farmacevtski sestavek za zdravljenje multiple skleroze
EP13710308.1A EP2812351B1 (en)	2012-02-10	2013-02-08	Pharmaceutical composition for the treatment of multiple sclerosis
ES13710308.1T ES2684725T3 (es)	2012-02-10	2013-02-08	Composiciones farmacéuticas para el tratamiento de la esclerosis múltiple
HUE13710308A HUE039044T2 (hu)	2012-02-10	2013-02-08	Gyógyászati kompozíció sclerosis multiplex kezelésére
PT137103081T PT2812351T (pt)	2012-02-10	2013-02-08	Composição farmacêutica para o tratamento de esclerose múltipla
US16/053,217 US20190201484A1 (en)	2012-02-10	2018-08-02	Pharmaceutical composition for the treatment of multiple sclerosis

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PL398077A PL398077A1 (pl)	2012-02-10	2012-02-10	Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego

Publications (1)

Publication Number	Publication Date
PL398077A1 true PL398077A1 (pl)	2012-08-27

Family

ID=46762685

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL398077A PL398077A1 (pl)	2012-02-10	2012-02-10	Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
PL13710308T PL2812351T3 (pl)	2012-02-10	2013-02-08	Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL13710308T PL2812351T3 (pl)	2012-02-10	2013-02-08	Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego

Country Status (9)

Country	Link
US (2)	US20150080313A1 (pl)
EP (1)	EP2812351B1 (pl)
DK (1)	DK2812351T3 (pl)
ES (1)	ES2684725T3 (pl)
HU (1)	HUE039044T2 (pl)
PL (2)	PL398077A1 (pl)
PT (1)	PT2812351T (pl)
SI (1)	SI2812351T1 (pl)
WO (1)	WO2013117742A2 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2016414E (pt) *	2006-05-05	2015-11-24	Opexa Therapeutics	Vacina de células t
HUE029899T2 (en) *	2008-01-25	2017-04-28	Vianex S A	Therapeutic, mannan-linked MBP83-99 myelin basic protein peptide

2012
- 2012-02-10 PL PL398077A patent/PL398077A1/pl unknown
2013
- 2013-02-08 WO PCT/EP2013/052615 patent/WO2013117742A2/en not_active Ceased
- 2013-02-08 ES ES13710308.1T patent/ES2684725T3/es active Active
- 2013-02-08 PT PT137103081T patent/PT2812351T/pt unknown
- 2013-02-08 PL PL13710308T patent/PL2812351T3/pl unknown
- 2013-02-08 DK DK13710308.1T patent/DK2812351T3/en active
- 2013-02-08 EP EP13710308.1A patent/EP2812351B1/en active Active
- 2013-02-08 US US14/377,903 patent/US20150080313A1/en not_active Abandoned
- 2013-02-08 SI SI201331085T patent/SI2812351T1/sl unknown
- 2013-02-08 HU HUE13710308A patent/HUE039044T2/hu unknown
2018
- 2018-08-02 US US16/053,217 patent/US20190201484A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150080313A1 (en)	2015-03-19
WO2013117742A3 (en)	2014-02-20
DK2812351T3 (en)	2018-07-09
ES2684725T3 (es)	2018-10-04
WO2013117742A2 (en)	2013-08-15
EP2812351B1 (en)	2018-03-28
EP2812351A2 (en)	2014-12-17
PT2812351T (pt)	2018-08-01
PL2812351T3 (pl)	2018-09-28
SI2812351T1 (sl)	2018-11-30
HUE039044T2 (hu)	2018-12-28
US20190201484A1 (en)	2019-07-04

Publication	Publication Date	Title
MX2017004592A (es)	2017-07-10	Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
PH12016500619A1 (en)	2016-06-13	Dry powder inhaler
PE20142319A1 (es)	2015-01-24	Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MY167691A (en)	2018-09-21	A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
BR112015027297A8 (pt)	2018-01-30	administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
NZ704011A (en)	2016-04-29	Abuse deterrent pharmaceutical compositions for controlled release
BR112015010106A2 (pt)	2017-08-22	Dosagem e administração de terapias para câncer com oligonucleotídeo
MX2013003635A (es)	2013-05-22	Compuestos de n-heteroarilo.
MX373851B (es)	2020-03-26	Métodos de administración de tratamiento con pirfenidona.
RU2015102772A (ru)	2016-10-10	Бензодиазелипы для мелкоклеточного рака легкого
EA201391689A1 (ru)	2014-05-30	Система доставки лекарственного средства
GB2523707A (en)	2015-09-02	Novel pharmaceutical formulations and their use in the treatment of periodontal disease
PH12015500653A1 (en)	2015-05-11	Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EP4700016A3 (en)	2026-03-25	Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
MD20140004A2 (en)	2014-05-31	Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
WO2015001163A3 (es)	2015-04-09	Nanopartículas lipídicas para la cicatrización de heridas
BR112015027436A2 (en)	2014-11-06	Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
WO2010098627A3 (ko)	2011-01-06	약제학적 제제
JP2014520892A5 (pl)	2016-06-16
WO2015009731A3 (en)	2015-03-19	Azacyclic constrained analogs of fty720
EA201591653A1 (ru)	2017-05-31	Композиции для лечения глазных расстройств с применением дипиридамола
IN2014DN10134A (pl)	2015-08-21
PL398077A1 (pl)	2012-08-27	Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
MX2015009681A (es)	2016-07-11	Un medicamento combinado que comprende finilefrina y paracetamol.
WO2013038200A3 (en)	2013-06-27	Neurodevelopmental disorders